A drug repurposing screen reveals dopamine signaling as a candidate therapeutic pathway for PIGA-CDG
- 1Department of Human Genetics, University of Utah School of Medicine, Salt Lake City, Utah, United States of America
Abstract
PIGA-CDG is a congenital disorder of glycosylation caused by pathogenic partial loss-of-function variants in the PIGA gene. PIGA encodes an enzyme responsible for the catalytic transfer of N-acetylglucosamine to phosphatidylinositol during the first step of glycosylphosphatidylinositol anchor biosynthesis. Loss of this enzyme has a widespread phenotypic impact, but primarily results in neurological symptoms including seizures, intellectual disability, and developmental delay. Currently, treatments are limited and focus on symptom management. We developed an eye model of PIGA-CDG that has a reduced eye size. We screened a library of 98% 1,520 FDA/EMA-approved compounds to find drugs that improved the small eye phenotype. This screen revealed numerous drugs that improved eye size, including those that targeted dopamine signaling and cyclooxygenases. Using pharmacological and genetic approaches, we show that modulating dopamine signaling improves the eye size. Genetic inhibition of dopamine 2 receptor signaling and dopamine reuptake improve both the eye model and neurologically relevant PIGA-CDG phenotypes, including seizures and locomotor deficits. We also pharmacologically and genetically validate cyclooxygenase targeting drugs in the eye model. These findings reveal novel biology underlying PIGA-CDG and point towards candidate therapeutic approaches. Author summary: PIGA-CDG is a rare neurodevelopmental disorder caused by pathogenic variants in the gene PIGA. Patients primarily display neurological symptoms, including seizures, developmental delay, and intellectual disability. Fewer than 100 patients have been identified, and treatment strategies are limited. In the context of rare diseases, de novo drug development is difficult due to the high cost, lengthy development times, and often too small of a patient population to conduct a clinical trial. Our lab leverages drug repurposing screening to circumvent many of the hurdles associated with de novo drug development. Here, we develop and screen FDA- or EMA-approved compounds on a Drosophila model of PIGA-CDG, uncovering novel biology underlying PIGA-associated pathophysiology. We use pharmacological and genetic tools to demonstrate that modifying dopamine signaling and abundance, as well as cyclooxygenase-mediated pathways, contribute to PIGA-associated phenotypes. This work highlights promising therapeutic targets for PIGA-CDG.
Related
- Metabolomic profiling in treated mucopolysaccharidosis IH reveals candidate biomarkers and adjunctive therapeutic pathways
- Repurposing the Insecticide Flufenerim, the Only Anti- Cryptococcus Compound Identified in the MMV Global Health Priority Box, as a Candidate for the Environmental Control of the Cryptococcosis Agents
- Repurposing niclosamide ethanolamine for alveolar echinococcosis reveals a disconnect between in vitro efficacy and in vivo outcome in the intraperitoneal infection model
- Identification of genetically supported candidate therapeutic targets for angina pectoris using mendelian randomization
- Ursolic acid as a multi-target therapeutic candidate in type 2 diabetes mellitus: a mechanistic and translational review
BibTeX
@article{aziz2026drug,
title = {{A drug repurposing screen reveals dopamine signaling as a candidate therapeutic pathway for PIGA-CDG}},
author = {Miriam C. Aziz and Jennie Wilson and Clement Y. Chow},
journal = {PLOS Genetics},
year = {2026},
month = aug,
doi = {10.1371/journal.pgen.1012294},
url = {https://journals.plos.org/plosgenetics/article?id=10.1371/journal.pgen.1012294},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - A drug repurposing screen reveals dopamine signaling as a candidate therapeutic pathway for PIGA-CDG
AU - Miriam C. Aziz
AU - Jennie Wilson
AU - Clement Y. Chow
PY - 2026
DA - 2026/08/31
JO - PLOS Genetics
DO - 10.1371/journal.pgen.1012294
UR - https://journals.plos.org/plosgenetics/article?id=10.1371/journal.pgen.1012294
AB - PIGA-CDG is a congenital disorder of glycosylation caused by pathogenic partial loss-of-function variants in the PIGA gene. PIGA encodes an enzyme responsible for the catalytic transfer of N-acetylglucosamine to phosphatidylinositol during the first step of glycosylphosphatidylinositol anchor biosynthesis. Loss of this enzyme has a widespread phenotypic impact, but primarily results in neurological symptoms including seizures, intellectual disability, and developmental delay. Currently, treatments are limited and focus on symptom management. We developed an eye model of PIGA-CDG that has a reduced eye size. We screened a library of 98% 1,520 FDA/EMA-approved compounds to find drugs that improved the small eye phenotype. This screen revealed numerous drugs that improved eye size, including those that targeted dopamine signaling and cyclooxygenases. Using pharmacological and genetic approaches, we show that modulating dopamine signaling improves the eye size. Genetic inhibition of dopamine 2 receptor signaling and dopamine reuptake improve both the eye model and neurologically relevant PIGA-CDG phenotypes, including seizures and locomotor deficits. We also pharmacologically and genetically validate cyclooxygenase targeting drugs in the eye model. These findings reveal novel biology underlying PIGA-CDG and point towards candidate therapeutic approaches. Author summary: PIGA-CDG is a rare neurodevelopmental disorder caused by pathogenic variants in the gene PIGA. Patients primarily display neurological symptoms, including seizures, developmental delay, and intellectual disability. Fewer than 100 patients have been identified, and treatment strategies are limited. In the context of rare diseases, de novo drug development is difficult due to the high cost, lengthy development times, and often too small of a patient population to conduct a clinical trial. Our lab leverages drug repurposing screening to circumvent many of the hurdles associated with de novo drug development. Here, we develop and screen FDA- or EMA-approved compounds on a Drosophila model of PIGA-CDG, uncovering novel biology underlying PIGA-associated pathophysiology. We use pharmacological and genetic tools to demonstrate that modifying dopamine signaling and abundance, as well as cyclooxygenase-mediated pathways, contribute to PIGA-associated phenotypes. This work highlights promising therapeutic targets for PIGA-CDG.
SN - 1553-7404
ER -